Health Canada approves Rinvoq to treat active ankylosing spondylitis.- AbbVie,
AbbVie announced that Health Canada has approved Rinvoq (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable. Rinvoq may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs (NSAIDS).
"Ankylosing spondylitis is a lifelong, progressive inflammatory disease that affects young people. AS is difficult to diagnose, and causes patients constant symptoms including pain and stiffness, particularly in the spine,which results in significant impairment of a person's quality of life ,"said Walter Maksymowych, Professor of Medicine, University of Alberta, and Chief Medical Officer, CARE Arthritis. "To date, there have been limited treatments options for people living with AS, so it is very encouraging to now have a new, oral therapeutic choice available for patients."
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins